Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• The renin-angiotensin-aldosterone system (RAAS) plays a key role in cardiovascular disease (CVD) and renal disease pathophysiology.
• RAAS activation is linked to increased risk of cardiovascular (CV) and renal events.
• RAAS blockade with ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB) is proven to reduce CV and renal morbidity and mortality.

Purpose of the Study:

• To evaluate the potential benefits of combined RAAS blockade using ACEIs and ARBs.
• To explore the distinct and complementary pharmacologic effects of ACEIs and ARBs.
• To identify patient populations that may benefit from dual RAAS inhibition.

Main Methods:

• Review of large-scale, long-term clinical trials on RAAS blockade.
• Analysis of clinical trial data on combination therapy with ACEIs and ARBs.
• Identification of patient subgroups with chronic RAAS activation.

Main Results:

• RAAS blockade with ACEIs or ARBs significantly decreases CV and renal morbidity and mortality.
• Some benefits of RAAS blockade are independent of blood pressure reduction.
• Combination therapy with ACEI plus ARB appears rational for patients with chronic RAAS activation, including those with heart failure, diabetes, proteinuria, or impaired renal function.

Conclusions:

• Dual RAAS inhibition with ACEIs and ARBs may be a rational therapeutic strategy in specific high-risk patient populations.
• Further large-scale clinical endpoint trials are needed to confirm the benefits of dual RAAS inhibition.
• Understanding the distinct pharmacologic effects of ACEIs and ARBs supports their combined use in managing complex cardiovascular and renal conditions.